Botulinum Neurotoxin in Tremors, Tics, Hemifacial Spasm, Spasmodic Dysphonia, and Stuttering

Botulinum Toxin: Therapeutic Clinical Practice and Science

Volumn , Issue , 2009, Pages 112-130

  Bentivoglio, Anna Rita ^a,b   Fasano, Alfonso ^a,b   Albanese, Alberto ^a,c  

^a UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 60049093186     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-4928-9.00010-X     Document Type: Chapter

References (136)

1. Frueh BR, Felt TH, Wojno TH, Musch DC Treatment of blepharospasm with botulinum toxin: a preliminary report. Arch Ophthalmol 1984, 102:1464-1468.
2. Mauriello JA Blepharospasm, Meige syndrome, and hemifacial spasm: treatment with botulinum toxin. Neurology 1985, 35:1499-1500.
3. Jankovic J, Schwartz K Botulinum toxin treatment of tremors. Neurology 1991, 41:1185-1188.
4. Blitzer A, Brin MF Laryngeal dystonia: a series with botulinum toxin therapy. Ann Otol Rhinol Laryngol 1991, 100:85-89.
5. Jankovic J Botulinum toxin in the treatment of dystonic tics. Mov Disord 1994, 9:347-349.
6. Digre K, Corbett JJ Hemifacial spasm: differential diagnosis, mechanism, and treatment. Adv Neurol 1988, 49:151-176.
7. Stamey W, Jankovic J The other Babinski sign in hemifacial spasm. Neurology 2007, 69:402-404.
8. Wang A, Jankovic J Hemifacial spasm: clinical findings and treatment. Muscle Nerve 1998, 21:1740-1747.
9. Martinelli P, Giuliani S, Ippoliti M Hemifacial spasm due to peripheral injury of facial nerve: a nuclear syndrome?. Mov Disord 1992, 7:181-184.
10. Tan EK, Jankovic J Bilateral hemifacial spasm: a report of five cases and a literature review. Mov Disord 1999, 14:345-349.
11. Mauriello JA, Leone T, Dhillon S, Pakeman B, Mostafavi R, Yepez MC Treatment choices of 119 patients with hemifacial spasm over 11 years. Clin Neurol Neurosurg 1996, 98:213-216.
12. Alexander GE, Moses H Carbamazepine for hemifacial spasm. Neurology 1982, 32:286-287.
13. Ryu H, Yamamoto S A simple technique for neurovascular decompression of the cranial nerves. Br J Neurosurg 2000, 14:132-134.
14. Kurokawa Y, Maeda Y, Toyooka T, Inaba K Microvascular decompression for hemifacial spasm caused by the vertebral artery: a simple and effective transposition method using surgical glue. Surg Neurol 2004, 61:398-403.
15. Piatt JH, Wilkins RH Microvascular decompression for tic douloureux. Neurosurgery 1984, 15:456.
16. Loeser JD, Chen J Hemifacial spasm: treatment by microsurgical facial nerve decompression. Neurosurgery 1983, 13:141-146.
17. Chung SS, Chang JH, Choi JY, Chang JW, Park YG Microvascular decompression for hemifacial spasm: a long-term follow-up of 1,169 consecutive cases. Stereotact Funct Neurosurg 2001, 77:190-193.
18. Badr-El-Dine M, El-Garem HF, Talaat AM, Magnan J Endoscopically assisted minimally invasive microvascular decompression of hemifacial spasm. Otol Neurotol 2002, 23:122-128.
19. Goto Y, Matsushima T, Natori Y, Inamura T, Tobimatsu S Delayed effects of the microvascular decompression on hemifacial spasm: a retrospective study of 131 consecutive operated cases. Neurol Res 2002, 24:296-300.
20. Samii M, Gunther T, Iaconetta G, Muehling M, Vorkapic P, Samii A Microvascular decompression to treat hemifacial spasm: long-term results for a consecutive series of 143 patients. Neurosurgery 2002, 50:712-718.
21. Wirtschafter JD, McLoon LK Long-term efficacy of local doxorubicin chemomyectomy in patients with blepharospasm and hemifacial spasm. Ophthalmology 1998, 105:342-346.
22. Ito M, Hasegawa M, Hoshida S, Miwa T, Furukawa M Successful treatment of hemifacial spasm with selective facial nerve block using doxorubicin (adriamycin) under local anesthesia. Acta Otolaryngol 2004, 124:217-220.
23. Flanders M, Chin D, Boghen D Botulinum toxin: preferred treatment for hemifacial spasm. Eur Neurol 1993, 33:316-319.
24. Jost WH, Kohl A Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm. J Neurol 2001, 248(Suppl 1):21-24.
25. Park YC, Lim JK, Lee DK, Yi SD Botulinum a toxin treatment of hemifacial spasm and blepharospasm. J Korean Med Sci 1993, 8:334-340.
26. Yoshimura DM, Aminoff MJ, Tami TA, Scott AB Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve 1992, 15:1045-1049.
27. Taylor JD, Kraft SP, Kazdan MS, Flanders M, Cadera W, Orton RB Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: a Canadian multicentre study. Can J Ophthalmol 1991, 26:133-138.
28. Elston JS The management of blepharospasm and hemifacial spasm. J Neurol 1992, 239:5-8.
29. Jitpimolmard S, Tiamkao S, Laopaiboon M Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. J Neurol Neurosurg Psychiatry 1998, 751-757.
30. Defazio G, Abbruzzese G, Girlanda P, Vacca L, Curra A, De Salvia R, et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 2002, 59:418-420.
31. Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 2002, 17:1288-1293.
32. Mejia NI, Vuong KD, Jankovic J Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 2005, 20:592-597.
33. Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, et al. Botulinum neurotoxin for the treatment of movement disorders: an evidence-based review. Neurology 2008, 70:1699-1706.
34. Cakmur R, Ozturk V, Uzunel F, Donmez B, Idiman F Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol 2002, 249:64-68.
35. Jankovic J, Schwartz K, Donovan DT Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990, 53:633-639.
36. Frei K, Truong DD, Dressler D Botulinum toxin therapy of hemifacial spasm: comparing different therapeutic preparations. Eur J Neurol 2006, 13(Suppl. 1):30-35.
37. Wan XH, Vuong KD, Jankovic J Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms. Chin Med Sci J 2005, 20:44-47.
38. Tousi B, Perumal JS, Ahuja K, Ahmed A, Subramanian T Effects of botulinum toxin-B (BTX-B) injections for hemifacial spasm. Parkinsonism Relat Disord 2004, 10:455-456.
39. Van den Bergh P, Francart J, Mourin S, Kollmann P, Laterre EC Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve 1995, 18:720-729.
40. Chen RS, Lu CS, Tsai CH Botulinum toxin A injection in the treatment of hemifacial spasm. Acta Neurol Scand 1996, 94:207-211.
41. Ainsworth JR, Kraft SP Long-term changes in duration of relief with botulinum toxin treatment of essential blepharospasm and hemifacial spasm. Ophthalmology 1995, 102:2036-2040.
42. Shorr N, Seiff SR, Kopelman J The use of botulinum toxin in blepharospasm. Am J Ophthalmol 1985, 99:542-546.
43. Dutton JJ, Buckley EG Long-term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology 1988, 95:1529-1534.
44. Ruusuvaara P, Setala K Long-term treatment of involuntary facial spasms using botulinum toxin. Acta Ophthalmol (Copenh) 1990, 68:331-338.
45. Chong PN, Ong B, Chan R Botulinum toxin in the treatment of facial dyskinesias. Ann Acad Med Singapore 1991, 20:223-227.
46. Biglan AW, May M Treatment of facial spasm with Oculinum (C. botulinum toxin. )J Pediatr Ophthalmol Strabismus 1986, 23:216-221.
47. Mauriello JA, Coniaris H, Haupt EJ Use of botulinum toxin in the treatment of one hundred patients with facial dyskinesias. Ophthalmology 1987, 94:976-979.
48. Yu YL, Fong KY, Chang CM Treatment of idiopathic hemifacial spasm with botulinum toxin. Acta Neurol Scand 1992, 85:55-57.
49. Borodic GE Hemifacial spasm: evaluation and therapy. Textbook of Botulinum Toxin Therapy 1994, 331-353. Marcel Dekker, New York. J. Jankovic, M. Hallett (Eds.).
50. Frueh BR, Musch DC Treatment of facial spasm with botulinum toxin. An interim report. Ophthalmology 1986, 93:917-923.
51. Carruthers J, Stubbs HA Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion. Can J Neurol Sci 1987, 14:42-45.
52. Borodic GE, Ferrante R, Pearce LB, Smith K Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord 1994, 9:31-39.
53. Savino P, Sergott R, Bosley T, Schatz N Hemifacial spasm treated with botulinum A toxin injection. Arch Ophthalmol 1985, 103:1305-1306.
54. Elston JS Botulinum toxin treatment of hemifacial spasm. J Neurol Neurosurg Psychiatry 1986, 49:827-829.
55. Tang X, Wan X Comparison of Botox with a Chinese type A botulinum toxin. Chin Med J (Engl) 2000, 113:794-798.
56. Rieder CR, Schestatsky P, Socal MP, Monte TL, Fricke D, Costa J, et al. A double-blind, randomized, crossover study of Prosigne versus Botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol 2007, 30:39-42.
57. Eleopra R, Tugnoli V, Rossetto O, Montecucco C, De Grandis D Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci Lett 1997, 224:91-94.
58. Blitzer A, Brin MF, Fahn S, Lovelace RE Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia). Laryngoscope 1988, 98:193-197.
59. Marsden CD, Sheehy MP Spastic dysphonia, Meige disease and torsion dystonia. Neurology 1982, 32:1202-1203.
60. Blitzer A, Lovelace RE, Brin MF, Fahn S, Fink ME Electromyographic findings in focal laryngeal dystonia. Ann Otol Rhinol Laryngol 1985, 94:591-594.
61. Cannito MP, Johnson JP Spastic dysphonia: a continuum disorder. J Commun Disord 1981, 14:215-233.
62. Blitzer A, Brin MF, Fahn S, Lovelace RE Clinical and laboratory characteristics of focal laryngeal dystonia: study of 110 cases. Laryngoscope 1988, 98:636-640.
63. Adler CH, Edwards BW, Bansberg SF Female predominance in spasmodic dysphonia. J Neurol Neurosurg Psychiatry 1997, 63:688.
64. Schweinfurth JM, Billante M, Courey MS Risk factors and demographics in patients with spasmodic dysphonia. Laryngoscope 2002, 112:220-223.
65. Stewart CF, Allen EL, Tureen P, Diamond BE, Blitzer A, Brin MF Adductor spasmodic dysphonia: standard evaluation of symptoms and severity. J Voice 1997, 11:95-103.
66. Brin MF, Fahn S, Blitzer A, Ramig LO, Stewart C Movement disorders of the larynx. Neurological Disorders of the Larynx 1992, 240-248. Thieme, New York. A. Blitzer, M.F. Brin, C.T. Sasaki, S. Fahn, K. Harris (Eds.).
67. Murry T, Woodson GE Combined-modality treatment of adductor spasmodic dysphonia with botulinum toxin and voice therapy. J Voice 1995, 9:460-465.
68. Truong DD, Bhidayasiri R Botulinum toxin therapy of laryngeal muscle hyperactivity syndromes: comparing different botulinum toxin preparations. Eur J Neurol 2006, 13(Suppl 1):36-41.
69. Weed DT, Jewett BS, Rainey C, Zealear DL, Stone RE, Ossoff RH, et al. Long-term follow-up of recurrent laryngeal nerve avulsion for the treatment of spastic dysphonia. Ann Otol Rhinol Laryngol 1996, 105:592-601.
70. Berke GS, Blackwell KE, Gerratt BR, Verneil A, Jackson KS, Sercarz JA Selective laryngeal adductor denervation-reinnervation: a new surgical treatment for adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 1999, 108:227-231.
71. Allegretto M, Morrison M, Rammage L, Lau DP Selective denervation: reinnervation for the control of adductor spasmodic dysphonia. J Otolaryngol 2003, 32:185-189.
72. Su CY, Chuang HC, Tsai SS, Chiu JF Transoral approach to laser thyroarytenoid myoneurectomy for treatment of adductor spasmodic dysphonia: short-term results. Ann Otol Rhinol Laryngol 2007, 116:11-18.
73. Clinical use of botulinum toxin. NIH Consensus Statement 1990, 8:1-20.
74. Blitzer A, Brin MF, Stewart C, Aviv JE, Fahn S Abductor laryngeal dystonia: a series treated with botulinum toxin. Laryngoscope 1992, 102:163-167.
75. Blitzer A, Brin MF, Stewart CF Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 1998, 108:1435-1441.
76. Sulica L, Behrman A Management of benign vocal fold lesions: a survey of current opinion and practice. Ann Otol Rhinol Laryngol 2003, 112:827-833.
77. Blitzer A, Brin MF, Fahn S, Lange D, Lovelace RE Botulinum toxin for the treatment of spastic dysphonia. Laryngoscope 1986, 96:1300-1301.
78. Troung DD, Rontal M, Rolnick M, Aronson AE, Mistura K Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope 1991, 101:630-634.
79. Boutsen F, Cannito MP, Taylor M, Bender B Botox treatment in adductor spasmodic dysphonia: a meta-analysis. J Speech Lang Hear Res 2002, 45:469-481.
80. Watts C, Nye C, Whurr R Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): a systematic Cochrane review. Clin Rehabil 2006, 20:112-122.
81. Albanese A, Barnes MP, Bhatia KP, Fernandez-Alvarez E, Filippini G, Gasser T, et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol 2006, 13:433-444.
82. Ford CM, Bless DM, Lowery JD Indirect laryngoscopic approach for injection of botulinum in spasmodic dysphonia. Otolaryngol Head Neck Surg 1990, 103:752-758.
83. Rhew K, Fiedler DA, Ludlow CL Technique for injection of botulinum toxin through the flexible nasolaryngoscope. Otolaryngol Head Neck Surg 1994, 111:787-794.
84. Green DC, Ward PH, Berke GS, Gerratt BR Point-touch technique of botulinum toxin injection for the treatment of spasmodic dysphonia. Ann Otol Rhinol Laryngol 1992, 101:883-887.
85. Miller RH, Woodson GE, Jankovic J Botulinum toxin injection in the vocal fold for spasmodic dysphonia. A preliminary report. Arch Otolaryngol Head Neck Surg 1987, 113:603-605.
86. Ludlow CL, Naunton RF, Sedory SE, Schulz GM, Hallett M Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology 1988, 38:1220-1225.
87. Bielamowicz S, Stager SV, Badillo A, Godlewski A Unilateral versus bilateral injections of botulinum toxin in patients with adductor spasmodic dysphonia. J Voice 2002, 16:117-123.
88. Maloney AP, Morrison MD A comparison of the efficacy of unilateral versus bilateral botulinum toxin injections in the treatment of adductor spasmodic dysphonia. J Otolaryngol 1994, 23:160-164.
89. Zwirner P, Murry T, Woodson GE A comparison of bilateral and unilateral botulinum toxin treatments for spasmodic dysphonia. Eur Arch Otorhinolaryngol 1993, 250:271-276.
90. Galardi G, Guerriero R, Amadio S, Leocani L, Teggi R, Melloni G, et al. Sporadic failure of botulinum toxin treatment in usually responsive patients with adductor spasmodic dysphonia. Neurol Sci 2001, 22:303-306.
91. Klotz DA, Maronian NC, Waugh PF, Shahinfar A, Robinson L, Hillel AD Findings of multiple muscle involvement in a study of 214 patients with laryngeal dystonia using fine-wire electromyography. Ann Otol Rhinol Laryngol 2004, 113:602-612.
92. Inagi K, Ford CN, Bless DM, Heisey D Analysis of factors affecting botulinum toxin results in spasmodic dysphonia. J Voice 1996, 10:306-313.
93. Brin MF, Fahn S, Moskowitz C, Friedman A, Shale HM, Greene PE, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Dystonia 2 1988, 599-608. Raven, New York. S. Fahn, C.D. Marsden, D.B. Calne (Eds.).
94. Brin MF, Blitzer A, Fahn S, Gould W, Lovelace RE Adductor laryngeal dystonia (spastic dysphonia): treatment with local injections of botulinum toxin (Botox). Mov Disord 1989, 4:287-296.
95. Whurr R, Nye C, Lorch M Meta-analysis of botulinum toxin treatment of spasmodic dysphonia: a review of 22 studies. Int J Lang Commun Disord 1998, 33(Suppl):327-329.
96. Blitzer A, Sulica L Botulinum toxin: basic science and clinical uses in otolaryngology. Laryngoscope 2001, 111:218-226.
97. Koriwchak MJ, Netterville JL, Snowden T, Courey M, Ossoff RH Alternating unilateral botulinum toxin type A (BOTOX) injections for spasmodic dysphonia. Laryngoscope 1996, 106:1476-1481.
98. Rontal M, Rontal E, Rolnick M, Merson R, Silverman B, Truong DD A method for the treatment of abductor spasmodic dysphonia with botulinum toxin injections: a preliminary report. Laryngoscope 1991, 101:911-914.
99. Meleca RJ, Hogikyan ND, Bastian RW A comparison of methods of botulinum toxin injection for abductory spasmodic dysphonia. Otolaryngol Head Neck Surg 1997, 117:487-492.
100. Ludlow CL, Naunton RF, Terada S, Anderson BJ Successful treatment of selected cases of abductor spasmodic dysphonia using botulinum toxin injection. Otolaryngol Head Neck Surg 1991, 104:849-855.
101. Bielamowicz S, Squire S, Bidus K, Ludlow CL Assessment of posterior cricoarytenoid botulinum toxin injections in patients with abductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 2001, 110:406-412.
102. Stong BC, DelGaudio JM, Hapner ER, Johns MM, III Safety of simultaneous bilateral botulinum toxin injections for abductor spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 2005, 131:793-795.
103. Cyrus CB, Bielamowicz S, Evans FJ, Ludlow CL Adductor muscle activity abnormalities in abductor spasmodic dysphonia. Otolaryngol Head Neck Surg 2001, 124:23-30.
104. Smith ME, Ford CN Resistance to botulinum toxin injections for spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 2000, 126:533-535.
105. Guntinas-Lichius O Injection of botulinum toxin type B for the treatment of otolaryngology patients with secondary treatment failure of botulinum toxin type A. Laryngoscope 2003, 113:743-745.
106. Adler CH, Bansberg SF, Krein-Jones K, Hentz JG Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia. Mov Disord 2004, 19:1075-1079.
107. Blitzer A Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia. Otolaryngol Head Neck Surg 2005, 133:836-838.
108. Grillone GA, Blitzer A, Brin MF, Annino DJ, Saint-Hilaire MH Treatment of adductor laryngeal breathing dystonia with botulinum toxin type A. Laryngoscope 1994, 104:30-32.
109. Zwirner P, Dressler D, Kruse E Spasmodic laryngeal dyspnea: a rare manifestation of laryngeal dystonia. Eur Arch Otorhinolaryngol 1997, 254:242-245.
110. Braun N, Abd A, Baer J, Blitzer A, Stewart C, Brin M Dyspnea in dystonia: a functional evaluation. Chest 1995, 107:1309-1316.
111. Zwirner P, Murry T, Woodson GE Effects of botulinum toxin on vocal tract steadiness in patients with spasmodic dysphonia. Eur Arch Otorhinolaryngol 1997, 254:391-395.
112. Ludlow CL Treatment of speech and voice disorders with botulinum toxin. JAMA 1990, 264:2671-2675.
113. Brin MF, Stewart C, Blitzer A, Diamond B Laryngeal botulinum toxin injections for disabling stuttering in adults. Neurology 1994, 44:2262-2266.
114. Aronson AE, Brown JR, Litin EM, Pearson JS Spastic dysphonia. II. Comparison with essential (voice) tremor and other neurologic and psychogenic dysphonias. J Speech Hear Disord 1968, 33:219-231.
115. Maronian NC, Waugh PF, Robinson L, Hillel AD Tremor laryngeal dystonia: treatment of the lateral cricoarytenoid muscle. Ann Otol Rhinol Laryngol 2004, 113:349-355.
116. Warrick P, Dromey C, Irish JC, Durkin L, Pakiam A, Lang A Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection. Laryngoscope 2000, 110:1366-1374.
117. Hertegard S, Granqvist S, Lindestad PA Botulinum toxin injections for essential voice tremor. Ann Otol Rhinol Laryngol 2000, 109:204-209.
118. Adler CH, Bansberg SF, Hentz JG, Ramig LO, Buder EH, Witt K, et al. Botulinum toxin type A for treating voice tremor. Arch Neurol 2004, 61:1416-1420.
119. Deuschl G, Bain P, Brin M Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Mov Disord 1998, 13(Suppl. 3):2-23.
120. Trosch RM, Pullman SL Botulinum toxin A injections for the treatment of hand tremors. Mov Disord 1994, 9:601-609.
121. Henderson JM, Ghika JA, Van Melle G, Haller E, Einstein R Botulinum toxin A in non-dystonic tremors. Eur Neurol 1996, 36:29-35.
122. Pullman S, Greene PF, Fahn S Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients. Arch Neurol 1996, 53:617-624.
123. Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord 1996, 11:250-256.
124. Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 2001, 56:1523-1528.
125. Papapetropoulos S, Singer C Treatment of primary writing tremor with botulinum toxin type a injections: report of a case series. Clin Neuropharmacol 2006, 29:364-367.
126. Schneider SA, Edwards MJ, Cordivari C, Macleod WN, Bhatia KP Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson's disease. Mov Disord 2006, 21:1722-1724.
127. Deuschl G, Lohle E, Heinen F, Lucking C Ear click in palatal tremor: its origin and treatment with botulinum toxin. Neurology 1991, 41:1677-1679.
128. Penney SE, Bruce IA, Saeed SR Botulinum toxin is effective and safe for palatal tremor: a report of five cases and a review of the literature. J Neurol 2006, 253:857-860.
129. Gordon K, Cadera W, Hinton G Successful treatment of hereditary trembling chin with botulinum toxin. J Child Neurol 1993, 8:154-156.
130. Gonzalez-Alegre P, Kelkar P, Rodnitzky RL Isolated high-frequency jaw tremor relieved by botulinum toxin injections. Mov Disord 2006, 21:1049-1050.
131. Kwak CH, Hanna PA, Jankovic J Botulinum toxin in the treatment of tics. Arch Neurol 2000, 57:1190-1193.
132. Marras C, Andrews D, Sime E, Lang AE Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 2001, 56:605-610.
133. Scott BL, Jankovic J, Donovan DT Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. Mov Disord 1996, 11:431-433.
134. Salloway S, Stewart CF, Israeli L, Morales X, Rasmussen S, Blitzer A, et al. Botulinum toxin for refractory vocal tics. Mov Disord 1996, 11:746-748.
135. Porta M, Maggioni G, Ottaviani F, Schindler A Treatment of phonic tics in patients with Tourette's syndrome using botulinum toxin type A. Neurol Sci 2004, 24:420-423.
136. Albanese A, Bentivoglio AR Botulinum toxin in movement disorders. Parkinson's Disease and Movement Disorders 2007, 605-619. Lippincott Williams & Wilkins, Philadelphia. 5th. J. Jankovic, E. Tolosa (Eds.).